Stedman's Medical Dictionary

gonad (go´nad)

An organ that produces sex cells; a testis or an ovary. [Mod. L. fr. G. *gone*, seed]
female ***g.*** *ovary*
indifferent ***g.*** the primordial organ in an embryo before its differentiation into testis or ovary. See indifferent *genitalia*.
male ***g.*** *testis*
streak ***g.*** *gonadal streak*

```
=> d his

     (FILE 'HOME' ENTERED AT 16:44:08 ON 09 APR 2001)

     FILE 'EUROPATFULL, PCTFULL, USPATFULL' ENTERED AT 16:44:55 ON 09 APR 2001
L1          6709 S TESTOSTERONE
L2          3769 S SILDENAFIL OR YOHIMBINE OR PENTOXIFYLINE OR APOMORPHINE OR
AL
L3           351 S L1(L)L2
L4           235 S L3(L)(SEX? OR DYSFUNCTION OR ERECT? OR IMPOTEN?)
L5           235 DUP REM L4 (0 DUPLICATES REMOVED)
L6            26 S L4/CLM
```

=> d ibib 9-26

L6 ANSWER 9 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1998057642 PCTFULL
TITLE (ENGLISH): ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
TITLE (FRENCH): ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1A
INVENTOR(S): PATANE, Michael, A.; BOCK, Mark, G.
PATENT ASSIGNEE(S): MERCK & CO., INC.
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9857642	A1	19981223

DESIGNATED STATES: AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GW HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.:	WO 1998-US12678	19980617
PRIORITY (ORIGINAL):	US 1997-60/050126	19970618
	GB 1998-9800234.8	19980106

L6 ANSWER 10 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1998057639 PCTFULL
TITLE (ENGLISH): ALPHA 1aADRENERGIC RECEPTOR ANTAGONISTS
TITLE (FRENCH): ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a
INVENTOR(S): PATANE, Michael, A.; BOCK, Mark, G.
PATENT ASSIGNEE(S): MERCK & CO., INC.
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9857639	A1	19981223

DESIGNATED STATES: AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GW HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.:	WO 1998-US12659	19980617
PRIORITY (ORIGINAL):	US 1997-60/050137	19970618
	GB 1998-9800456.7	19980109

L6 ANSWER 11 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1998057638 PCTFULL
TITLE (ENGLISH): ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
TITLE (FRENCH): ANTAGONISTES DES ADRENORECEPTEURS ALPHA 1a
INVENTOR(S): PATANE, Michael, A.; BOCK, Mark, G.; NEWTON, Randall, C.
PATENT ASSIGNEE(S): MERCK & CO., INC.
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9857638	A1	19981223

DESIGNATED STATES: AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GW HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1998-US12567 19980617
PRIORITY (ORIGINAL): US 1997-60/050959 19970618
GB 1998-9800217.3 19980107

L6 ANSWER 12 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1998057632 PCTFULL
TITLE (ENGLISH): ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
TITLE (FRENCH): ANTAGONISTES DES ADRENORECEPTEURS ALPHA 1a
INVENTOR(S): PATANE, Michael, A.; BOCK, Mark, G.; NAGARATHNAM, Dhanapalan; LAGU, Bharat; WONG, Wai, C.
PATENT ASSIGNEE(S): MERCK & CO., INC.; SYNAPTIC PHARMACEUTICAL CORPORATION
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9857632	A1	19981223

DESIGNATED STATES: AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GW HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1998-US12573 19980617
PRIORITY (ORIGINAL): US 1997-60/050136 19970618
GB 1998-9800219.9 19980107

L6 ANSWER 13 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1998056914 PCTFULL
TITLE (ENGLISH): MAMMALIAN MELANOCORTIN RECEPTORS AND USES
TITLE (FRENCH): RECEPTEURS DE MELANOCORTINE MAMMALIENS ET LEURS UTILISATIONS
INVENTOR(S): CONE, Roger, D.; CHEN, Wenbiao; LOW, Malcolm, J.
PATENT ASSIGNEE(S): OREGON HEALTH SCIENCES UNIVERSITY
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9856914	A1	19981217

DESIGNATED STATES: AU CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

APPLICATION INFO.: WO 1998-US12098 19980612
PRIORITY (ORIGINAL): US 1997-60/050063 19970613

L6 ANSWER 14 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1998043614 PCTFULL
TITLE (ENGLISH): DRUG PREPARATIONS FOR TREATING SEXUAL DYSFUNCTION
TITLE (FRENCH): PREPARATIONS MEDICAMENTEUSES POUR LE TRAITEMENT DE DYSFONCTIONS SEXUELLES
INVENTOR(S): DRIZEN, Alan; ROTHBART, Peter; NATH, Gary, M.
PATENT ASSIGNEE(S): LAM PHARMACEUTICALS, LLC
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9843614	A1	19981008

DESIGNATED STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.: WO 1998-US6020 19980327
PRIORITY (ORIGINAL): US 1997-08/825121 19970328

L6 ANSWER 15 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1998031368 PCTFULL
TITLE (ENGLISH): DOSAGE FORMS AND METHOD FOR AMELIORATING MALE ERECTILE DYSFUNCTION
TITLE (FRENCH): FORMES ET PROCEDES PHARMACEUTIQUES DESTINES A AMELIORER LES DYSERECTIONS CHEZ L'HOMME
INVENTOR(S): JOHNSON, Edward, Stewart; CLARKE, Anthony; GREEN, Richard, David
PATENT ASSIGNEE(S): R.P. SCHERER LIMITED
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9831368	A1	19980723

DESIGNATED STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.: WO 1998-GB143 19980116
PRIORITY (ORIGINAL): GB 1997-9700878.3 19970117

L6 ANSWER 16 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1997029735 PCTFULL
TITLE (ENGLISH): DERMAL PENETRATION ENHANCERS AND DRUG DELIVERY SYSTEMS INVOLVING

	SAME
TITLE (FRENCH):	PROMOTEURS DE PENETRATION DERMIQUE ET SYSTEME D'ADMINISTRATION DE MEDICAMENTS COMPRENANT CES PROMOTEURS
INVENTOR(S):	REED, Barry, Leonard; MORGAN, Timothy, Matthias; FINNIN, Barrie, Charles
PATENT ASSIGNEE(S):	MONASH UNIVERSITY; REED, Barry, Leonard; MORGAN, Timothy, Matthias; FINNIN, Barrie, Charles
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

NUMBER	KIND	DATE
WO 9729735	A1	19970821

DESIGNATED STATES:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SG SI SK TJ TM TR TT UA UG US UZ VN YU KE LS MW SD SZ UG AM AZ BY KG KZ TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI GN ML MR NE SN TD TG
APPLICATION INFO.:	WO 1997-AU91 19970219
PRIORITY (ORIGINAL):	AU 1996-PN 8144 19960219

L6 ANSWER 17 OF 26	PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER:	1996040136 PCTFULL
TITLE (ENGLISH):	ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST
TITLE (FRENCH):	ANTAGONISTES DU RECEPTEUR 'alpha'-ADRENERGIQUE 1a
INVENTOR(S):	PATANE, Michael, A.; BOCK, Mark, G.; FREIDINGER, Roger, M.; PONTICELLO, Rose, Ann; NEWTON, Randall, C.
PATENT ASSIGNEE(S):	MERCK & CO., INC.; PATANE, Michael, A.; BOCK, Mark, G.; FREIDINGER, Roger, M.; PONTICELLO, Rose, Ann; NEWTON, Randall, C.
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

NUMBER	KIND	DATE
WO 9640136	A1	19961219

DESIGNATED STATES:	AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KG KR KZ LK LR LT LV MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN KE LS MW SD SZ AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT BJ CF CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.:	WO 1996-US9425 19960606
PRIORITY (ORIGINAL):	US 1995-8/488272 19950607

L6 ANSWER 18 OF 26	PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER:	1996040135 PCTFULL
TITLE (ENGLISH):	ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
TITLE (FRENCH):	ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a
INVENTOR(S):	PATANE, Michael, A.; BOCK, Mark, G.; FREIDINGER, Roger, M.
PATENT ASSIGNEE(S):	MERCK & CO., INC.; PATANE, Michael, A.; BOCK, Mark, G.; FREIDINGER, Roger, M.
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

NUMBER	KIND	DATE

	WO 9640135 A1 19961219
DESIGNATED STATES:	AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KG KR KZ LK LR LT LV MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN KE LS MW SD SZ AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT BJ CF CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.:	WO 1996-US9363 19960604
PRIORITY (ORIGINAL):	US 1995-8/488267 19950607

L6 ANSWER 19 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent

ACCESSION NUMBER:	1996025934 PCTFULL
TITLE (ENGLISH):	ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
TITLE (FRENCH):	ANTAGONISTES DU RECEPTEUR ALPHA-1a-ADRENERGIQUE
INVENTOR(S):	EVANS, Ben, E.; PONTICELLO, Gerald, S.; HOFFMAN, Jacob, M.; CHANG, Raymond, S., L.
PATENT ASSIGNEE(S):	MERCK & CO., INC.; EVANS, Ben, E.; PONTICELLO, Gerald, S.; HOFFMAN, Jacob, M.; CHANG, Raymond, S., L.
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

NUMBER	KIND	DATE
WO 9625934	A1	19960829

DESIGNATED STATES:	AL AM AU AZ BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KR KZ LK LR LT LV MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US US UZ VN KE LS MW SD AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE CF CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.:	WO 1996-US2534 19960223
PRIORITY (ORIGINAL):	US 1995-8/392699 19950223
	US 1995-60/002534 19950818
	GB 1996-9603457.4 19960219

L6 ANSWER 20 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent

ACCESSION NUMBER:	1996014897 PCTFULL
TITLE (ENGLISH):	DEVICE FOR THE TRANSDERMAL ADMINISTRATION OF MEDICAMENTS TO TREAT THE MALE ERECTILE IMPOTENCE
TITLE (FRENCH):	DISPOSITIF D'ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS POUR LE TRAITEMENT DE L'IMPUISSANCE ERECTILE MASCULINE
INVENTOR(S):	MILLOT, Philippe; LAMOISE, Michel
PATENT ASSIGNEE(S):	LABORATOIRES D'HYGIENE ET DE DIETETIQUE (L.H.D.); MILLOT, Philippe; LAMOISE, Michel
LANGUAGE OF PUBL.:	French
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

NUMBER	KIND	DATE
WO 9614897	A1	19960523

DESIGNATED STATES:	AU CA CZ HU JP KR NZ PL SG SK US AT BE CH DE DK ES FR GB GR IE IT LU MC SE
APPLICATION INFO.:	WO 1995-FR1510 19951116
PRIORITY (ORIGINAL):	FR 1994-94/13716 19941116

L6 ANSWER 21 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent

24

ACCESSION NUMBER: 1992003141 PCTFULL
TITLE (ENGLISH): TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT OF MALE IMPOTENCE
TITLE (FRENCH): COMPOSITIONS TOPIQUES ET PROCEDES POUR LE TRAITEMENT DE L'IMPUISSANCE CHEZ l'HOMME
INVENTOR(S): EL-RASHIDY, Ragab
PATENT ASSIGNEE(S): PHARMEDIC CO.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9203141	A1	19920305

DESIGNATED STATES: AT BE CH DE DK ES FR GB GR IT JP LU NL SE
APPLICATION INFO.: WO 1991-US6028 19910826
PRIORITY (ORIGINAL): US 1990-573518 19900827

L6 ANSWER 22 OF 26 USPATFULL
ACCESSION NUMBER: 2000:88191 USPATFULL
TITLE: Apomorphine and sildenafil composition
INVENTOR(S): El-Rashidy, Ragab, Deerfield, IL, United States
PATENT ASSIGNEE(S): Pentech Pharmaceuticals, Inc., Buffalo Grove, IL, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6087362	20000711
APPLICATION INFO.:	~~US 1999-270035~~	19990316 (9)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Henley, III, Raymond
LEGAL REPRESENTATIVE: Olson & Hierl, Ltd.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 23 OF 26 USPATFULL
ACCESSION NUMBER: 2000:31051 USPATFULL
TITLE: Drug preparations for treating sexual dysfunction
INVENTOR(S): Drizen, Alan, Ontario, Canada
Rothbart, Peter, Ontario, Canada
Nath, Gary M., Bethesda, MD, United States
PATENT ASSIGNEE(S): L.A.M. Pharmaceutical Corp., Miami, FL, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6036977	20000314
APPLICATION INFO.:	US 1998-48335	19980326 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-825121, filed on 28 Mar 1997, now patented, Pat. No. US 5952006

which

is a continuation-in-part of Ser. No. US 1997-796578, filed on 6 Feb 1997, now patented, Pat. No. US 5897880 which is a continuation-in-part of Ser. No. US 1995-536750, filed on 29 Sep 1995, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Harrison, Robert H.
LEGAL REPRESENTATIVE: Nath, Gary M.; Yarnell, Scott F.Nath & Associates
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
LINE COUNT: 934
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 26 USPATFULL
ACCESSION NUMBER: 1999:53087 USPATFULL
TITLE: Device for percutaneous administration of medicaments for treating male impotence
INVENTOR(S): Millot, Philippe, Dijon, France
Lamoise, Michel, Bessey-les-Citeaux, France
PATENT ASSIGNEE(S): Laboratoires D'Hygiene et de Dietetique (L.H.D.), Paris, France (non-U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5899875	19990504	
	WO 9614897	19960523	
APPLICATION INFO.:	US 1997-836350	19970512	(8)
	WO 1995-FR1510	19951116	
		19970512	PCT 371 date
		19970512	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1994-13716	19941116

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Coggins, Wynn Wood
ASSISTANT EXAMINER: Finkel, Sharon
LEGAL REPRESENTATIVE: Stevens, Davis, Miller & Mosher, L.L.P.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 379

L6 ANSWER 25 OF 26 USPATFULL
ACCESSION NUMBER: 1999:893 USPATFULL
TITLE: Venous flow control element for maintaining penile erection
INVENTOR(S): Place, Virgil A., Kawaihae, HI, United States
PATENT ASSIGNEE(S): Vivus, Incorporated, Mountain View, CA, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5855548	19990105	
APPLICATION INFO.:	US 1997-782867	19970110	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-664423, filed on 14 Jun 1996, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Bahr, Jennifer
ASSISTANT EXAMINER: Kearney, Rosiland
LEGAL REPRESENTATIVE: Reed, Dianne E.Bozicevic & Reed LLP
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 956

L6 ANSWER 26 OF 26 USPATFULL
ACCESSION NUMBER: 1998:30702 USPATFULL
TITLE: Medication for impotence containing lyophilized roe and
a powdered extract of Ginkgo biloba
INVENTOR(S): Omar, Lotfy Ismail, P.O. Box F396, Kew Gardens, NY, United States 11415

	NUMBER	DATE
PATENT INFORMATION:	US 5730987	19980324
APPLICATION INFO.:	US 1996-660875	19960610 (8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Naff, David M.
ASSISTANT EXAMINER: Kerr, Janet M.
LEGAL REPRESENTATIVE: Kroll, Michael I.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 478

L6 . . . ANSWER 21 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent

CLM In this invention, a peripheral vasodilator which enhances the maintenance of penis **erection** by a male is combined with a pharmacologically acceptable enhancer to facilitate absorption of the vasodilator through the skin and a pharmacologically acceptable topical. . . 2-methylcyclodextrin. This most preferred cyclodextrin for the composition herein is hydroxypropyl-p-cyclodextrin (HPBCD herein). This invention is particularly useful to diabetic men who have become **impotent** as a result of their diabetes.

An alpha receptor blocker may be combined with the peripheral vasodilator, if desired. A preferred alpha receptor blocker is **phentolamine** which is represented by the formula:

other suitable alpha receptor blockers are phenoxybenzamine, **yohimbine**, prazosin, tolazoline and the like. These blockers are usually present in a concentration of about 0.05 to about 0.5 percent by weight of. . . range of about 20:1 to about 200:1, preferably about 30:1 to about 50:1. Optionally, the present compositions can also include androgens such as **testosterone** and the like.

Maintenance of penis **erection** may be further enhanced by restricting blood flow from the penis after the **erection** is enhanced by the peripheral vasodilator.

. . .
of the vasoconstrictor should be time delayed to act upon the penis after the peripheral vasodilator has enhanced the maintenance of the penis **erection**. This time delay may be accomplished by utilizing water-insoluble, lipophilic norepinephrine salts (such as benzoate) which will slowly be absorbed through the skin. . .

9 1
TABLE I
REPRESENTATIVE TOPICAL PAPAVERINE GELS
C
Gel Preparation
Ing edients, wt%
Papaverine HCl 1 3.0 3.0 3.0 3.0 3.0 3.0 3.0
Phentolamine
myselate 2 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Norepinephrine 3 0.001 0.001 0.001 0.001 0.001 0.001 0
Ethanol 35.0 30.0 30.0 35.0. . .

To enhance an **erection**, a sufficient amount of the present composition is applied directly to the penis prior to coitus. The topical composition containing papaverine and HPBCD. . .

An effective amount or dosage needed to enhance an **erection** usually is about 50 to about 500

milligrams of the peripheral vasodilator per application. Preferably, about 75 to about 150 milligrams of the. . .

. . .

of trials have been conducted under physician supervision in volunteers diagnosed with premature ejaculation and who have not been able to maintain an **erection** for coitus. These patients were young, healthy subjects with normal vascular integrity and were undergoing treatment with intracavernosal injections of 30 mg doses. . . 11; 50 mg dose of papaverine). The patients were asked for a subjective evaluation of efficacy based on the quality of their **erection** (rigidity) and the duration of action. The patients were instructed to apply the topical preparation in the following manner; 1. Empty entire contents. . .

. . .

tumescence and duration. There were no reports of irritation. In those patients that experienced a positive response to treatment, the duration of their **erections** were approximately 10-15 minutes as compared to one hour with injection, and 2 minutes or less with no drug treatments.

CLAIMS ..CLM:
I CLAIMS
1. An aqueous topical composition suitable for enhancing the maintenance of penis **erection** by a male patient which comprises a peripheral vasodilator and hy4roxypropyl-p-cyclodextrin present in a molar ratio in the range of about 1 to. . . 1.4, respectively, and in a pharmacologically acceptable topical vehicle for said vasodilator; said peripheral vasodilator being present in an amount sufficient to enhance penis **erection**.

9. The composition in accordance with claim 4 wherein said alpha receptor blocker is **phentolamine**.

16. A method for enhancing the maintenance of penis **erection** by a male patient which comprises the topical application to the penis of an effective, **erection** enhancing, amount of a composition comprising a peripheral vasodilator and a hydroxypropyl-p-cyclodextrin in a pharmacologically acceptable topical vehicle for said vasodilator and. . .

18. The method in accordance with claim 16 wherein the peripheral vasodilator is papaverine and wherein the composition additionally includes 6 **phentolamine**.

19. The method in accordance with claim 16 further comprising a means for restricting blood flow from the penis after the penis **erection** is enhanced.

L6 ANSWER 22 OF 26 USPATFULL

CLM What is claimed is:

1. A method suitable for treating **erectile dysfunction** in a human patient which comprises administering to said patient prior to **sexual** activity **apomorphine** or a pharmaceutically acceptable acid addition salt thereof and **sildenafil** or a pharmaceutically acceptable acid addition salt thereof each being administered in an amount sufficient to induce and maintain an **erection** adequate for sustaining satisfaction during **sexual** activity but less than an amount that induces substantial nausea.

2. The method in accordance with claim 1 wherein the **apomorphine** and **sildenafil** are co-administered in a single dosage unit comprising about 1 to about 6 mg **apomorphine** and about 10 to about 75 mg **sildenafil**.

3. The method in accordance with claim 2 wherein the single dosage unit comprises about 2 to about 5 mg **apomorphine** and about 15 to about 50 mg **sildenafil**.

4. The method in accordance with claim 1 wherein the **sildenafil** and **apomorphine** is sequentially administered by first administering a dosage unit comprising **sildenafil** in an amount in the range of about 10 to about 75 mg and then a dosage unit comprising **apomorphine** in an amount in the range of about 1 to about 6 mg.

5. The method in accordance with claim 4 wherein the amount of administered **apomorphine** is in a range of about 2 to 5 mg.

6. The method in accordance with claim 4 wherein the amount of administered **sildenafil** is in a range of about 15 to about 50 mg.

7. The method in accordance with claim 4 wherein the amount of administered **apomorphine** is in a range of about 2 to about 5 mg and the amount of administered **sildenafil** is in a range of about 15 to about 50 mg.

8. The method in accordance with claim 4 wherein the **sildenafil** is administered within about 30-60 minutes of **apomorphine** administration.

10. A pharmaceutical composition comprising **sildenafil** and **apomorphine** in a pharmaceutically acceptable vehicle.

11. The composition of claim 10 wherein the amount of **sildenafil** is in the range of about 10 to about 25 mg.

12. The composition of claim 10 wherein the amount of **apomorphine** is in the range of about 1 to about 6 mg.

14. A pharmaceutical composition comprising **sildenafil** and a cyclodextrin in a pharmaceutically acceptable vehicle.

16. The composition of claim 15 wherein the amount of **sildenafil** is about 20 mg and the amount of hydroxypropyl-beta-cyclodextrin is

about 1 to about 10% by weight of the total. . .

17. The composition of claim 10 further including **erectogenic** agents selected from adrenal steroids, alpha receptor blockers, or peripheral vasodilators added at a concentration in the range of about 50 to about 100 percent by weight of the weight of **apomorphine** .

18. The composition of claim 17 wherein the **erectogenic** agent is an adrenal steroid selected from the group consisting of **testosterone** and dehydroepiandrosterone.

19. The composition of claim 17 wherein the **erectogenic** agent is an alpha receptor blocker selected from the group consisting of **phentolamine, yohimbine**, prazosin, doxazosin, terazosin, and trimazosin.

20. The composition of claim 17 wherein the **erectogenic** agent is prostaglandin E.sub.1.

L6 . . . MicroPatent 15

CLM CLAIMS
The use of a pharmaceutical composition for oral administration comprising a carrier and active ingredient selected from a dopamine agonist, **testosterone** and mixtures thereof, the composition being in the form of a fast-dispersing dosage form designed to release the active ingredient rapidly in the oral cavity for the manufacture of a medicament for treatment of male **erectile dysfunction**.

claims in which the dopamine agonist is **apomorphine** or a salt thereof.

10. The use as claimed in any preceding claim in which the active ingredient comprises **testosterone**.

ii. The use as claimed in claim 10 in which the is **testosterone** is present in an amount of 10 to 100mg.

12. A method of treating male **erectile dysfunction** which comprises administering to the oral cavity of a patient a dopamine agonist and/or **testosterone** in a fast-dispersing dosage form designed to release active ingredients rapidly in the oral cavity.

16

L6 . . . 23. A drug delivery system according to any one of claims 11 to 22,
characterised in
that the physiologically active agent is **testosterone**,
oestradiol,
ethinyloestradiol,
progesterone, norethisterone acetate, ibuprofen, ketoprofen,
flurbiprofen, naproxen,
diclofenac, fentanyl, buprenorphine, scopolamine, prochlorperazine,
metochlopramide,
ondansetron, tamoxifen, epitiostanol, exemestane, 4-hydroxy-androstenedione and its
derivatives, finasteride, turosteride, LY191704, MK-306, alprazolarn,
alprostadil,
prostacylcin and its derivatives, melatonin, ri-docosanol, tromantadine,
lipophilic pro-drugs
of acyclovir, low molecular weight heparin, enoxaparin, surnatriptan,
amlodipine,
nitrendipine, primaquine, minoxidil, minoxidil pro-drugs, pilocarpine,
salbutarnol,
terbutaline, salmeterol,. . .

29. A method according to claim 28, characterised in that the disease or condition
requires male hormone replacement in **testosterone** deficient
hypogonadal
men, female
hormone replacement therapy for postmenopausal women, androgen replacement therapy
for females lacking libido, male contraception or female contraception.
. . .

soft
tissue injury, narcotic withdrawal, severe post-operative pain, motion sickness, oestrogen
dependent breast cancer, prostatic enlargement and/or prostatic cancer, alopecia and acne,
anxiety disorders, male **impotence**, Raynauds syndrome and
varicose veins,
sleep disorders,
jetlag, herpes virus infections, deep vein thrombosis, migraine, high blood pressure, malaria,
diagnosis of cystic fibrosis, asthma. . .

L6 ANSWER 14 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent

CLM 1. A method for the treatment of **sexual dysfunction** in an animal, which comprises:

topically applying to a specific site on the surface of an animal a therapeutically effective amount of a drug for treating **sexual dysfunction** dispersed within a gelled composition comprising a polymer matrix which is suspended in a liquid medium, wherein the polymer matrix contains a negative. . .

6. The method of claim 1, wherein the drug for treating **sexual dysfunction** is effective intreating **impotency** in a male.

7. The method of claim 1, wherein the drug for treating **sexuai dysfunction** is effective intreating vaginal dryness in a female.

12. The method of claim 1, wherein the drug for treating **sexual** disfunction is selected from the group consisting of papaverine, **phentolamine**, prostaglandin E,, nicotinic acid, glycerol, propylene glycol, **testosterone**, **testosterone** propionate, glucocorticoids, hydrocortisone, gamma-linolenic acid (GLA), dihomo-gamma-linolenic acid (DGLA) and mixtures thereof.

. . .
method of claim 1, wherein the is therapeutically effective amount of the drug penetrates the exterior layers of the penis causing an **erection** without significantly modifying motor or sensory functions.

15. A method for the treatment of **erectile dysfunction** in a male animal, which comprises:

topically applying to the surface of a penisa therapeutically effective amount of a drug for treating **impotency** dispersed within a gelled composition comprising a polymer matrix which is suspended in a liquid medium; wherein the polymer matrix contains a. . .

24. The method of claim 15, wherein the drug for treating **impotency** is selected from the group consisting of papaverine, **phentolamine**, prostaglandin E,, and mixtures thereof.

25. The method of claim 15, wherein the therapeutically effective dose penetrates the exterior layers of the penis causing an **erection** without significantly modifying motor or sensory functions. .

26. A gelled composition for treating **impotency**, which comprises: therapeutically effective amounts of a drug for treating **impotency** dispersed within a matrix containing a negative charged polymer blended with a nonionic polymer, wherein the molar ratio of the negative

charged polymer. . .

31. A method for the treatment of **erectile dysfunction** in male animals, which comprises:

39. The method of claim 31, wherein the drug dispersed in the gelled composition is selected from the group consisting of papaverine, **phentolamine**, prostaglandin El. and mixtures thereof.

40. The method of claim 31, wherein the therapeutically effective dose penetrates the exterior layers of the penis causing an **erection** without significantly modifying motor or sensory functions.

41. A method for the treatment of **sexual dysfunction** resulting from vaginal dryness in a female animal, which comprises:

topically applying to a vagina a therapeutically effective amount of a drug for treating female **sexual dysfunction** caused by vaginal dryness dispersed within a gelled composition comprising a polymer matrix which is suspended in a liquid medium; wherein the. . .

46. The method of claim 41,wherein the drug for treating **sexual dysfunction** caused by vaginal dryness is
selected from the group consisting of prostaglandin E,, nicotinic acid, glycerol, propylene glycol, **testosterone**, **testosterone** propionate, glucocorticoids, hydrocortisone, gamma-linolenic acid (GLA), dihomo -gamma - 1 inolenic acid (DGLA), Yerba Santa extract and mixtures thereof.

47. A gelled composition for treating **sexual dysfunction** resulting in vaginal dryness, which comprises:

is therapeutically effective amounts of a drug for treating **sexual dysfunction** caused by vaginal dryness dispersed
within a matrix containing a negative charged polymer having a mean average molecular weight between about 650,000 and. . .

49. The gelled composition of claim 47, wherein the drug for treating **sexual dysfunction** caused by vaginal
dryness is selected from the group consisting of prostaglandin E,, nicotinic acid, glycerol, propylene glycol, **testosterone**, **testosterone** proplonate, glucocorticoids, hydrocortisone, gamma-linolenic acid (GLA) , dihomo -gamma- 1 inolenic acid (DGLA) , Yerba Santa extract and mixtures thereof.

=> d ibib 1-5

L9 ANSWER 1 OF 5 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1998043614 PCTFULL
TITLE (ENGLISH): DRUG PREPARATIONS FOR TREATING SEXUAL DYSFUNCTION
TITLE (FRENCH): PREPARATIONS MEDICAMENTEUSES POUR LE TRAITEMENT DE DYSFONCTIONS SEXUELLES
INVENTOR(S): DRIZEN, Alan; ROTHBART, Peter; NATH, Gary, M.
PATENT ASSIGNEE(S): LAM PHARMACEUTICALS, LLC
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9843614	A1	19981008

DESIGNATED STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.: WO 1998-US6020 19980327
PRIORITY (ORIGINAL): US 1997-08/825121 19970328

L9 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1998031368 PCTFULL
TITLE (ENGLISH): DOSAGE FORMS AND METHOD FOR AMELIORATING MALE ERECTILE DYSFUNCTION
TITLE (FRENCH): FORMES ET PROCEDES PHARMACEUTIQUES DESTINES A AMELIORER LES DYSERECTIONS CHEZ L'HOMME
INVENTOR(S): JOHNSON, Edward, Stewart; CLARKE, Anthony; GREEN, Richard, David
PATENT ASSIGNEE(S): R.P. SCHERER LIMITED
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9831368	A1	19980723

DESIGNATED STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.: WO 1998-GB143 19980116
PRIORITY (ORIGINAL): GB 1997-9700878.3 19970117

L9 ANSWER 3 OF 5 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1993015104 PCTFULL
TITLE (ENGLISH): 20-SUBSTITUTED PREGNENE DERIVATIVES AND THEIR USE AS

ANDROGEN
SYNTHESIS INHIBITORS
TITLE (FRENCH): DERIVES DE PREGNENE SUBSTITUES EN POSITION 20 ET LEUR UTILISATION
EN TANT QU'INHIBITEURS DE LA SYNTHESE D'ANDROGENES
INVENTOR(S): BRODIE, Angela; LI, Jisong
PATENT ASSIGNEE(S): RESEARCH CORPORATION TECHNOLOGIES, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9315104	A1	19930805

DESIGNATED STATES: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1993-US760 19930128
PRIORITY (ORIGINAL): US 1992-7/827040 19920129

L9 ANSWER 4 OF 5 USPATFULL
ACCESSION NUMBER: 2000:31051 USPATFULL
TITLE: Drug preparations for treating sexual dysfunction
INVENTOR(S): Drizen, Alan, Ontario, Canada
Rothbart, Peter, Ontario, Canada
Nath, Gary M., Bethesda, MD, United States
PATENT ASSIGNEE(S): L.A.M. Pharmaceutical Corp., Miami, FL, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6036977	20000314
APPLICATION INFO.:	US 1998-48335	19980326 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-825121, filed on 28 Mar 1997, now patented, Pat. No. US 5952006 which
is a continuation-in-part of Ser. No. US 1997-796578, filed on 6 Feb 1997, now patented, Pat. No. US 5897880 which is a continuation-in-part of Ser. No. US 1995-536750, filed on 29 Sep 1995, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Harrison, Robert H.
LEGAL REPRESENTATIVE: Nath, Gary M.; Yarnell, Scott F.Nath & Associates
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
LINE COUNT: 934
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 5 USPATFULL
ACCESSION NUMBER: 1998:30702 USPATFULL
TITLE: Medication for impotence containing lyophilized roe and
a powdered extract of Ginkgo biloba
INVENTOR(S): Omar, Lotfy Ismail, P.O. Box F396, Kew Gardens, NY, United States 11415

	NUMBER	DATE
PATENT INFORMATION:	US 5730987	19980324
APPLICATION INFO.:	US 1996-660875	19960610 (8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Naff, David M.
ASSISTANT EXAMINER: Kerr, Janet M.
LEGAL REPRESENTATIVE: Kroll, Michael I.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 478

=> d kwic 1-5

L9 ANSWER 1 OF 5 PCTFULL COPYRIGHT 2001 MicroPatent

CLM 46. The method of claim 41,wherein the drug for treating **sexual dysfunction** caused by vaginal dryness is selected from the group consisting of prostaglandin E,, nicotinic acid, glycerol, propylene glycol, **testosterone**, **testosterone** propionate, glucocorticoids, hydrocortisone, gamma-linolenic acid (GLA), dihomo -gamma - 1 inolenic acid (DGLA), Yerba Santa extract and mixtures thereof.

49. The gelled composition of claim 47, wherein the drug for treating **sexual dysfunction** caused by vaginal dryness is selected from the group consisting of prostaglandin E,, nicotinic acid, glycerol, propylene glycol, **testosterone**, **testosterone** proplonate, glucocorticoids, hydrocortisone, gamma-linolenic acid (GLA) , dihomo -gamma- 1 inolenic acid (DGLA) , Yerba Santa extract and mixtures thereof.

L9 . . . MicroPatent

CLM CLAIMS
The use of a pharmaceutical composition for oral administration comprising a carrier and active ingredient selected from a dopamine agonist, **testosterone** and mixtures thereof, the composition being in the form of a fast-dispersing dosage form designed to release the active ingredient rapidly in the oral cavity for the manufacture of a medicament for treatment of male **erectile dysfunction**.

12. A method of treating male **erectile dysfunction** which comprises administering to the oral cavity of a patient a dopamine agonist and/or **testosterone** in a fast-dispersing dosage form designed to release active ingredients rapidly in the oral cavity.

L9 ANSWER 3 OF 5 PCTFULL COPYRIGHT 2001 MicroPatent

CLM The 5(alpha)-reductase inhibitors, 4-MA and finasteride, were noted to increase **testosterone** levels [18]. Although this effect may be beneficial in treating men with BPH without causing gynecomastia and **impotence**, inhibition of all androgen production is an important goal

of treatment for prostatic cancer. The 20-substituted-pregnene derivatives, of which 4-pregnen-3-one-20(beta)-aldoxime is an. . . example, may be of value in this treatment because of their dual action in reducing androgen production by inhibiting synthesis of the subtrate (**testosterone**) and the activity of the 5(alpha)-reductase.

L9 ANSWER 4 OF 5 USPATFULL

CLM What is claimed is:

36. The method of claim 33, wherein the drug for treating **sexual dysfunction** caused by vaginal dryness is selected from the group consisting of prostaglandin E.sub.1, nicotinic acid, glycerol, propylene glycol, **testosterone**, **testosterone** propionate, glucocorticoids, hydrocortisone, gamma-linolenic acid (GLA), dihomo-gamma-linolenic acid (DGLA), Yerba Santa extract and mixtures thereof.

39. The gelled composition of claim 37, wherein the drug for treating **sexual dysfunction** caused by vaginal dryness is selected from the group consisting of prostaglandin E.sub.1, nicotinic acid, glycerol, propylene glycol, **testosterone**, **testosterone** propionate, glucocorticoids, hydrocortisone, gamma-linolenic acid (GLA), dihomo-gamma-linolenic acid (DGLA), Yerba Santa extract and mixtures thereof.

L9 ANSWER 5 OF 5 USPATFULL

CLM What is claimed is:

8. The composition for treating **impotence** in human males according to claim 6, wherein said hormone is **testosterone** or a derivative thereof.